Literature DB >> 16690617

Regulation of neuronal nitric-oxide synthase activity by somatostatin analogs following SST5 somatostatin receptor activation.

Pierre Cordelier1, Jean-Pierre Estève, Souad Najib, Luis Moroder, Nicole Vaysse, Lucien Pradayrol, Christiane Susini, Louis Buscail.   

Abstract

Somatostatin receptor SST5 is an inhibitory G protein-coupled receptor that exerts a strong cytostatic effect on various cell types. We reported previously that the SST5 anti-proliferative effect results in the inhibition of mitogen-induced increases in intracellular cGMP levels and MAPK activity. This study was conducted to define the early molecular events accountable for the SST5-mediated anti-proliferative effect. Here, we demonstrate that, in Chinese hamster ovary cells expressing SST5 (CHO/SST5 cells), somatostatin inhibited cell proliferation induced by nitric oxide donors and overexpression of the neuronal nitric-oxide synthase (nNOS) protein isoform. Accordingly, nNOS activity and dimerization were strongly inhibited following SST5 activation by the somatostatin analog RC-160. In CHO/SST5 cells, nNOS was dynamically recruited by the SST5 receptor and phosphorylated at tyrosyl residues following RC-160 treatment. RC-160 induced SST5-p60(src) kinase complex formation and subsequent p60(src) kinase activation. Coexpression of an inactive p60(src) kinase mutant with SST5 blocked RC-160-induced nNOS phosphorylation and inactivation and prevented the SST5-mediated anti-proliferative effect. In CHO/SST5 cells, p60(src) kinase associated with nNOS to induce its inactivation by phosphorylation at tyrosyl residues following RC-160 treatment. Using recombinant proteins, we demonstrated that such phosphorylation prevented nNOS homodimerization. Next, surface plasmon resonance and mutation analysis revealed that p60(src) directly associated with nNOS phosphorylated Tyr604. SST5-mediated inhibition of nNOS activity was demonstrated to be essential to the RC-160 anti-proliferative effect on pancreatic endocrine tumor-derived cells. We therefore identified nNOS as a new p60(src) kinase substrate essential for SST5-mediated anti-proliferative action.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690617     DOI: 10.1074/jbc.M602024200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes.

Authors:  S Y Yao; A Ljunggren-Rose; N Chandramohan; W O Whetsell; S Sriram
Journal:  J Neuroimmunol       Date:  2010-08-19       Impact factor: 3.478

Review 2.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

3.  The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function.

Authors:  Guisheng Zhou; Marie-Claude Gingras; Shi-He Liu; Donghui Li; Zhijun Li; Robbi L Catania; Kelly M Stehling; Min Li; Giovanni Paganelli; Richard A Gibbs; Francesco J Demayo; William E Fisher; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

4.  The role of the neuropeptide somatostatin on methamphetamine and glutamate-induced neurotoxicity in the striatum of mice.

Authors:  Lauriaselle Afanador; Ina Mexhitaj; Carolyn Diaz; Dalila Ordonez; Lisa Baker; Jesus A Angulo
Journal:  Brain Res       Date:  2013-03-19       Impact factor: 3.252

5.  Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects.

Authors:  Kyle P Smith; Kathleen M Gifford; Joshua S Waitzman; Sarah E Rice
Journal:  Proteins       Date:  2014-11-18

Review 6.  Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.

Authors:  Mehtap Cakir; Dorota Dworakowska; Ashley Grossman
Journal:  J Cell Mol Med       Date:  2010-11       Impact factor: 5.310

Review 7.  Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.

Authors:  Federico Gatto; Federica Barbieri; Marica Arvigo; Stefano Thellung; Jessica Amarù; Manuela Albertelli; Diego Ferone; Tullio Florio
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

8.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.